A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Upadacitinib on Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (SLEEP UP)
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Upadacitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms SLEEP UP
- Sponsors AbbVie
Most Recent Events
- 13 Sep 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.(strategic decision)
- 03 May 2024 New trial record